Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/62407
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEkasin Anupongsanugoolen_US
dc.contributor.authorSupanimit Teekachunhateanen_US
dc.contributor.authorNoppamas Rojanasthienen_US
dc.contributor.authorSaipin Pongsathaen_US
dc.contributor.authorChaichan Sangdeeen_US
dc.date.accessioned2018-09-11T09:26:54Z-
dc.date.available2018-09-11T09:26:54Z-
dc.date.issued2005-03-03en_US
dc.identifier.issn14726904en_US
dc.identifier.issn14726904en_US
dc.identifier.other2-s2.0-27544434452en_US
dc.identifier.other10.1186/1472-6904-5-2en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=27544434452&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/62407-
dc.description.abstractBackground: Isoflavones from soybeans may provide some beneficial impacts on postmenopausal health. The purpose of this study was to compare the pharmacokinetics and bioavailability of plasma isoflavones (daidzein and genistein) after a single dose of orally administered soy beverage and soy extract capsules in postmenopausal Thai women. Methods: We conducted a randomized two-phase crossover pharmacokinetic study in 12 postmenopausal Thai women. In the first phase, each subject randomly received either 2 soy extract capsules (containing daidzin: genistin = 7.79 : 22.57 mg), or soy beverage prepared from 15 g of soy flour (containing daidzin : genistin = 9.27 : 10.5 1 mg). In the second phase, the subjects received an alternative preparation in the same manner after a washout period of at least 1 week. Blood samples were collected immediately before and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 32 h after administration of the soy preparation in each phase. Plasma daidzein and genistein concentrations were determined by using high performance liquid chromatography (HPLC). The pharmacokinetic parameters of daidzein and genistein, i.e. maximal plasma concentration (Cmax.), time to maximal plasma concentration (Tmax). area under the plasma concentration time curve (AUC) and half-life (t1/2)1 were estimated using the TopFit version 2.0 software with noncompartmental model analysis. Results: There were no significant differences in the mean values of Cmax/dose, AUC0-32/dose, AUC0-∞/dose, Tmax, and t1/2 of genistein between both preparations. For pharmacokinetic parameters of daidzein, the mean values of Cmax/dose, Tmax, and t1/2 did not significantly differ between both preparations. Nonetheless, the mean AUC0-32/dose and AUC0-∞/dose after administration of soy extract capsules were slightly (but significantly, p < 0.05) higher than those of soy beverage. Conclusion: The bioavailability of daidzein, which was adjusted for the administered dose (AUC/dose), following a single oral administration of soy beverage was slightly (but significantly) less than that of soy extract capsules, whereas, the bioavailability adjusted for administered dose of genistein from both soy preparations were comparable. The other pharmacokinetic parameters of daidzein and genistein, including Cmax adjusted for the dose, Tmax and t1/2 were not different between both soy preparations. © 2005 Anupongsanugool et al; licensee BioMed Central Ltd.en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai womenen_US
dc.typeJournalen_US
article.title.sourcetitleBMC Clinical Pharmacologyen_US
article.volume5en_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.